Madrigal Pharmaceuticals, Inc.

Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH

Role: lead

Rezdiffra Pregnancy and Lactation Registry

Role: lead

Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)

Role: lead

Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)

Role: lead

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Function

Role: lead

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

Role: lead

A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

Role: lead

A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis

Role: lead

Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects

Role: lead

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients

Role: lead

Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy Subjects

Role: lead

Drug Interaction Study of MGL-3196 With Rosuvastatin and Simvastatin

Role: lead

Drug Interaction Study of MGL-3196 With Clopidogrel

Role: lead

Drug Interaction Study of MGL-3196 With Pioglitazone

Role: lead

Bioavailability Study of MGL-3196 Tablets Compared to Capsules

Role: lead

Radiolabeled Study to Determine the Mass Balance of [14C] MGL-3196

Role: lead

Drug Interaction Study of MGL-3196 With Atorvastatin

Role: lead

Ascending Multiple-Dose Study to Evaluate VIA-3196 in Healthy Subjects

Role: lead